期刊
ONCOTARGET
卷 7, 期 11, 页码 13013-13030出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.7344
关键词
acute lymphoblastic leukemia; HER2/neu; trastuzumab; rituximab; ADCC
资金
- Deutsche Jose Carreras Leukemia Foundation [DJS 04/08]
- Deutsche Krebshilfe [110465, 109620]
- Deutsche Forschungsgemeinschaft [SFB-685]
- Wilhelm Sander-Stiftung [2007.115.3]
The epidermal growth factor receptor HER2/neu is expressed on various cancers and represents a negative prognostic marker, but is also a target for the therapeutic monoclonal antibody Trastuzumab. In about 30% of cases, HER2/neu is expressed on acute lymphoblastic leukemia (ALL) cells and was proposed to be associated with a deleterious prognosis. Here we evaluated clinical data from 65 ALL patients (HER2/neu(+), n = 17; HER2/neu(-), n = 48) with a median follow-up of 19.4 months (range 0.6-176.5 months) and observed no association of HER2/neu expression with response to chemotherapy, disease free or overall survival. In vitro, treatment of primary ALL cells (CD20(+)HER2/neu(+), CD20(+)HER2/neu(-) and CD20(-)HER2/neu(-)) with Rituximab and Trastuzumab led to activation of NK cells in strict dependence of the expression of the respective antigen. NK reactivity was more pronounced with Rituximab as compared to Trastuzumab, and combined application could lead to additive effects in cases where both antigens were expressed. Besides providing evidence that HER2/neu expression is no risk factor in ALL patients, our data demonstrates that HER2/neu can be a promising target for Trastuzumab therapy in the subset of ALL patients with the potential to improve disease outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据